BioXcel Therapeutics, Inc. (BTAI) Form 8-K — May 15, 2026
BioXcel Therapeutics reported a net loss of $12.7 million for the first quarter of 2026, driven by $10.2 million in operating losses and $4.2 million in net interest expense. The company generated only $206,000 in revenue from its approved product IGALMI, while holding just $17.2 million in cash against $139.6 million in total liabilities. The filing contains critical going-concern language, stating that conditions raise 'substantial doubt about its ability to continue as a going concern.' This disclosure, combined with the significant debt load and minimal revenue, signals severe financial distress and a high risk of insolvency or forced restructuring.
Key figures
- Revenue
- 206000
- Total Debt
- 139568000
- Total Assets
- 34025000
- Cash Position
- 17180000
- Rd Expenses
- 2955000
- Sga Expenses
- 7191000
- Cost Of Goods Sold
- 283000
- Weighted Average Shares
- 23571000
Price after filing
Close on the filing date to close N calendar days later (from $1.21). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.